PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34228551-5	2021	In this study, we evaluated in vitro the nature of the mutations in the KPC-2 and KPC-3 ss-lactamase sequences (the most frequent KPC-type enzymes) that lead to CZA resistance, and the subsequent effects of these mutations on susceptibility to other ss-lactam antibiotics.	avibactam, ceftazidime drug combination	161-164	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	72-77	
34760723-10	2021	In brief, CZA resistance was caused mainly by bla KPC-2 duplication, and TGC resistance was caused by ramR inactivation with additional LPS changes due to IS element insertion in wbbL.	avibactam, ceftazidime drug combination	10-13	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	50-55	
34484166-3	2021	Here, we report the emergence of a novel KPC-2 variant, designated KPC-74, produced by K. pneumoniae strain KP55, that conferred CZA resistance in a patient after CZA exposure.	avibactam, ceftazidime drug combination	129-132	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	41-46	
34484166-3	2021	Here, we report the emergence of a novel KPC-2 variant, designated KPC-74, produced by K. pneumoniae strain KP55, that conferred CZA resistance in a patient after CZA exposure.	avibactam, ceftazidime drug combination	163-166	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	41-46	
34935448-15	2021	To the best of our knowledge, this is a novel KPC-2 variant conferring resistance to CZA and the first report of its emergence.	avibactam, ceftazidime drug combination	85-88	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	46-51	
35461077-5	2022	RESULTS: We report a case of emergence of CAZ-AVI resistance in ST 11 KPC-2-producing K. pneumoniae (KP-HX1016) during 14 days of exposure with CZA-AVI.	avibactam, ceftazidime drug combination	42-49	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	70-75	
35311523-2	2022	Herein, the basis of susceptibility to carbapenems and resistance to ceftazidime (CAZ) and CZA of the D179Y variant of KPC-2 and -3 was explored.	avibactam, ceftazidime drug combination	91-94	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	119-131	
33139291-8	2020	Most (90.1%) bla KPC-2-producers were susceptible to ceftazidime-avibactam.	avibactam, ceftazidime drug combination	53-74	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	17-22